Intellectual Property
Dec. 19, 2014
Ambry Genetics, McDermott win Federal Circuit patent ruling
The U.S. Court of Appeals for the Federal Circuit declared Wednesday that certain portions of three gene testing patents asserted by Myriad Genetics Inc. were ineligible for patent protection.
By Kevin Lee
Daily Journal Staff Writer
The U.S. Court of Appeals for the Federal Circuit declared Wednesday that certain portions of three gene testing patents asserted by Myriad Genetics Inc. were ineligible for patent protection.
The decision handed an important victory to Ambry Genetics Corp., an Aliso Viejo-based defendant, and Menlo Park-based McDermott Will & Emery partner Willaim G. Gaede.
Both companies offer medical kits that allow users to test for...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In